 | | Vol. 12.37 – 21 September, 2021 |
| |
|
|
| Investigators reported the long-term outcome of 27 patients with chronic lymphoid leukemia (CLL) treatment naïve with 17p deletion and/or TP53 mutation treated with ibrutinib alone or in combination with rituximab on a Phase II clinical study.
[Blood] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that pro-inflammatory oncostatin M (OSM) was an important regulator of HSC niches in the bone marrow (BM). OSM up-regulated E-selectin expression on BM endothelial cells indirectly increasing HSC proliferation.
[Leukemia] |
|
|
|
| Scientists highlighted RUNX1 and CEBPA transcription factor swapping as a feature of leukemia cell differentiation and revealed that FOXC1 prevented this by stabilizing enhancer binding of a RUNX1/HDAC1/TLE3 transcription repressor complex to oncogenic effect.
[Cell Reports] |
|
|
|
| DOT1L is a versatile histone H3K79 methyltransferase with a prominent role in mixed-lineage leukemia-fusion leukemia. The authors reported that DOT1L protein stability was regulated by the extracellular glucose level through the hexosamine biosynthetic pathway.
[Cell Reports] |
|
|
|
| To identify genetic defects that cooperated with Pax5 and Ebf1 compound heterozygosity to initiate leukemia, scientists performed a Sleeping Beaut transposon screen that identified cooperating partners including gain-of-function mutations in Stat5b and Jak1, or loss-of-function mutations in Cblb and Myb.
[Oncogene] |
|
|
|
| Researchers examined the effect of elevating NAD+ levels in models with reduced HSC potential, ATM-deficient and aged WT mice, and showed that supplementation of nicotinamide riboside, a NAD+ precursor, improved lymphoid lineage potential during supplementation.
[npj Aging and Mechanisms of Disease] |
|
|
|
| The authors examined the hematopoietic versus the non-hematopoietic role of p66Shc in regulating hematopoietic stem/progenitor cells traffic and blood flow recovery after ischemia in diabetic mice.
[Antioxidants & Redox Signaling] |
|
|
|
| Investigators identified the tetraspanin CD82 as a novel regulator of hematopoietic stem and progenitor cell (HSPC) mobilization. Combining AMD3100 and anti-CD82 treatments, they detected enhanced mobilization of mouse HSPCs and human CD34+ cells in animal models.
[Stem Cell Reports] |
|
|
|
| Although contributing to diet-induced obesity and fatty liver, suppressors of cytokine signaling 3 (SOCS3) were nevertheless critical to suppress excess myeloid hematopoiesis and severe systemic inflammation associated with intestinal dysbiosis on a high-fat diet.
[iScience] |
| |
|
|
| In this randomized, Phase II trial, eligible patients received either the control or idiotype-keyhole limpet hemocyanin vaccine, an auto-transplant, vaccine-specific co-stimulated T cells expanded ex vivo, and two booster doses of the assigned vaccine.
[Blood] |
|
|
|
| Researchers evaluated dasatinib-based two-step induction with the primary endpoint of three-year event-free survival as treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
[Blood Advances] |
|
|
|
| Scientists analyzed anti-SARS-CoV-2 spike IgG antibody titers and neutralizing Ab among 217 recipients of cellular treatments, such as allogeneic and autologous hematopoietic cell transplant and chimeric antigen receptor T cell therapy.
[Blood Cancer Discovery] |
|
|
|
|
| Investigators review the current knowledge of miRNAs function in different aspects of HSC biology, including consequences of aberrant miRNA expression, and discuss unsolved issues.
[Wiley Interdisciplinary Reviews-RNA] |
|
|
|
| The authors review current critical points of hematopoietic stem cell transplantation using alternative donors and assessing recently reported safety issues of gene therapy methods, and conclude that, although a breakthrough, the safety of gene therapy remains to be established.
[Bone Marrow Transplantation] |
|
|
|
| The pathophysiology of poor graft function can be conceptualized as dysfunction related to the number or productivity of the stem cell compartment, defects in bone marrow microenvironment components such as mesenchymal stromal cells and endothelial cells, or immunological suppression of post allogeneic stem cell transplant hematopoiesis.
[Blood Advances] |
|
|
|
|
| BeiGene, Ltd. announced that BRUKINSA® (zanubrutinib) has received accelerated approval from the US FDA for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen.
[BeiGene, Ltd.] |
|
|
|
|
|
|
|
| | Cellectis – Paris, France |
|
|
|
| | NHS Blood and Transplant – Oxford, England, United Kingdom |
|
|
|
| | Moores Cancer Center, UC San Diego – San Diego, California, United States |
|
|
|
| | Houston Methodist Research Institute – Houston, Texas, United States |
|
|
|
| | Lund University – Lund, Sweden |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
